Tags

Type your tag names separated by a space and hit enter

One-year soy isoflavone supplementation prevents early postmenopausal bone loss but without a dose-dependent effect.
J Nutr Biochem 2006; 17(8):509-17JN

Abstract

It is believed that soy isoflavone has much potential effectiveness on the postmenopausal status; however, the optimal dose for preventing postmenopausal bone loss still remains unclear. This open-labeled, self-controlled pilot study was undertaken to determine the effect of 1-year supplementation of different high dosages of soy isoflavone in postmenopausal Taiwanese women. Forty-three women aged 45-67 years were enrolled and randomly assigned into a control (C), 100 mg/day isoflavone (IF100) and 200 mg/day isoflavone (IF200) groups for 1 year. Dual-energy X-ray absorptiometry and other related biochemical markers of bone metabolism were measured. Results indicated that the decrease in bone mineral density (BMD) was significant for lumbar vertebrae L1-3, L1-4 and the femur neck in the C group; surprisingly, the BMD of L1-3 was significantly elevated in the IF100 group; however, there were no consistent responses in the IF200 group. No significant change except loss of the bone mineral content of Ward's triangle (P=.003) was found in the IF200 group after treatment. The percentage change at L1-3 was less (P=.04) in the IF200 group when compared to the IF100 group. A relatively uniform direction of bone formation in expanding the weight and area with different rates of change resulted in different BMD changes. Both indicated a change of bone formation patterns with the higher-dose supplement. A protective effect of IF100 on estrogen-related bone loss was observed. A lack of a benefit such as high safety in the IF200 group for 1-year administration was ensured and lacked undesirable side effects.

Authors+Show Affiliations

School of Pharmaceutical, Taipei Medical University, Taipei 110, Taiwan. sihuang@tmu.edu.twNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

16563719

Citation

Huang, Hui-Ying, et al. "One-year Soy Isoflavone Supplementation Prevents Early Postmenopausal Bone Loss but Without a Dose-dependent Effect." The Journal of Nutritional Biochemistry, vol. 17, no. 8, 2006, pp. 509-17.
Huang HY, Yang HP, Yang HT, et al. One-year soy isoflavone supplementation prevents early postmenopausal bone loss but without a dose-dependent effect. J Nutr Biochem. 2006;17(8):509-17.
Huang, H. Y., Yang, H. P., Yang, H. T., Yang, T. C., Shieh, M. J., & Huang, S. Y. (2006). One-year soy isoflavone supplementation prevents early postmenopausal bone loss but without a dose-dependent effect. The Journal of Nutritional Biochemistry, 17(8), pp. 509-17.
Huang HY, et al. One-year Soy Isoflavone Supplementation Prevents Early Postmenopausal Bone Loss but Without a Dose-dependent Effect. J Nutr Biochem. 2006;17(8):509-17. PubMed PMID: 16563719.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - One-year soy isoflavone supplementation prevents early postmenopausal bone loss but without a dose-dependent effect. AU - Huang,Hui-Ying, AU - Yang,Hsiao-Ping, AU - Yang,Hui-Ting, AU - Yang,Tung-Chuan, AU - Shieh,Ming-Jer, AU - Huang,Shih-Yi, Y1 - 2006/02/03/ PY - 2005/11/21/received PY - 2005/12/30/revised PY - 2006/01/03/accepted PY - 2006/3/28/pubmed PY - 2006/9/6/medline PY - 2006/3/28/entrez SP - 509 EP - 17 JF - The Journal of nutritional biochemistry JO - J. Nutr. Biochem. VL - 17 IS - 8 N2 - It is believed that soy isoflavone has much potential effectiveness on the postmenopausal status; however, the optimal dose for preventing postmenopausal bone loss still remains unclear. This open-labeled, self-controlled pilot study was undertaken to determine the effect of 1-year supplementation of different high dosages of soy isoflavone in postmenopausal Taiwanese women. Forty-three women aged 45-67 years were enrolled and randomly assigned into a control (C), 100 mg/day isoflavone (IF100) and 200 mg/day isoflavone (IF200) groups for 1 year. Dual-energy X-ray absorptiometry and other related biochemical markers of bone metabolism were measured. Results indicated that the decrease in bone mineral density (BMD) was significant for lumbar vertebrae L1-3, L1-4 and the femur neck in the C group; surprisingly, the BMD of L1-3 was significantly elevated in the IF100 group; however, there were no consistent responses in the IF200 group. No significant change except loss of the bone mineral content of Ward's triangle (P=.003) was found in the IF200 group after treatment. The percentage change at L1-3 was less (P=.04) in the IF200 group when compared to the IF100 group. A relatively uniform direction of bone formation in expanding the weight and area with different rates of change resulted in different BMD changes. Both indicated a change of bone formation patterns with the higher-dose supplement. A protective effect of IF100 on estrogen-related bone loss was observed. A lack of a benefit such as high safety in the IF200 group for 1-year administration was ensured and lacked undesirable side effects. SN - 0955-2863 UR - https://www.unboundmedicine.com/medline/citation/16563719/One_year_soy_isoflavone_supplementation_prevents_early_postmenopausal_bone_loss_but_without_a_dose_dependent_effect_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0955-2863(06)00021-0 DB - PRIME DP - Unbound Medicine ER -